Shares of luxury homebuilder

Toll Brothers Inc

(NYSE:

TOL

) are advancing Wednesday following an upbeat commentary on the company's prospects by an analyst at Wedbush.

Thehirschfeld theatre new york seating chart Toll Brothers Analyst

Jay McCanless

has an Outperform rating and a $48 price target for

Toll Brothers

. Wedbush also added the stock to its Best Ideas List.

The Toll Brothers Thesis

Order growth at Toll Brothers has surpassed expectations in the last two quarters, McCanless said in a Wednesday note. Given the easy prior year comps and sequential community growth through fiscal year 2020 ending October, the analyst sees double-digit percentage order growth as achievable for the remainder of the year.

The two price increases the homebuilder has already announced in 2020 and the likelihood of more increases should help profitability ramp from fiscal year 2020 to 2021, McCanless said.

The analyst expects 36% year-over-year EPS growth for 2021, as homes sold now will close starting in fiscal year 2021 and have 180 basis points higher gross margin than homes closed in 2020.

Share repurchase, according to the analyst, is another catalyst. The company signaled at its first quarter earnings call it would be an active buyer of its stock at current levels, McCanless noted.

Wedbush said valuation of shares are attractive, given they are trading at a discount to the homebuilder group, both on P/E basis and on the basis of Price/tangible book value.

TOLL Price Action

Toll Brothers shares were up 3.46% to $40.312.

Related Links

Analyst: Toll Brothers Holds 'Strong And Flexible Position,' Can Navigate Economic Challenges

Trade War Fears Trigger Nomura Instinet's Downgrade Of Housing Stocks

Photo by Tom Rumble on Unsplash

Latest Ratings for TOL

Feb 2020

Wedbush

Upgrades

Neutral

Outperform

Feb 2020

Raymond James

Downgrades

Outperform

Market Perform

Feb 2020

RBC Capital

Upgrades

Sector Perform

Sector Outperform

View More Analyst Ratings for TOL

View the Latest Analyst Ratings

See more from Benzinga

Nano-Cap Cellect Biotechnology Rips Higher On Medical Cannabis Deal

Tesla Blames COVID-19 Impact For Model 3 Hardware Botch In China, Promises Free Replacement

Vir Biotech, Alnylam Stitch COVID-19 Therapy Partnership

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View comments